Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
KIPO sided with generic drug makers of Crestor
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Nov 22, 2014 03:29:38
Korea Intellectual Property Office (KIPO) sided with twelve generic drug makers, ruling on November 21 that AstraZeneca’s patent on the use of a cholesterol lowering drug for Crestor 5 mg and 10mg is invalid.

Twelve companies who joined the lawsuit were BC World, SK Chemicals, MSD Korea, Hanmi, Daewon, Boryung, LG Life Sciences, Chong Kun Dang, Yuhan, Dong-A ST, and Kwangdong.

Generic drug makers rolled out their generic versions of Crestor 5mg and 10m in April, regardless of the possible patent issue.

A patent specialist of a pharmaceutical company said, “The ruling came late although the case had been filed before the patent expiration for the substance of Crestor. Now we can market our generic drugs without a risk.”

Industry experts said many pharmaceutical companies challenged the patent because they develop a combination drug of rosuvastatin and ezetimibe.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com